Investment analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a research note issued on Monday, Benzinga reports. The firm set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s target price indicates a potential upside of 61.04% from the stock’s current price.
Other analysts have also issued research reports about the stock. Wedbush initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday. They set a “buy” rating and a $40.00 target price on the stock. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They issued a “buy” rating for the company.
Read Our Latest Report on ORKA
Oruka Therapeutics Stock Performance
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Congress Members Are Buying These 3 Hot Stocks
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
- What is the Australian Securities Exchange (ASX)
- 3 Undervalued Stocks That Are Too Cheap to Ignore Right Now
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.